Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...

PHILADELPHIA--(BUSINESS WIRE)--FORE Biotherapeutics, a registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer, today presented new ...

Serial circulating tumor DNA analysis can demonstrate rapid clonal dynamics that evolve during response and resistance to both standard chemotherapy and targeted therapy of BRAF-mutant colon cancer ...

Pivotal results from the Phase 3 BREAKWATER trial showed 51% risk reduction in death compared to standard-of-care treatment BRAFTOVI combination regimen also demonstrated 47% risk reduction in disease ...

Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy ...

BRAF V600E-mutant metastatic CRC is associated with poor clinical outcomes, with a median overall survival of 17 months. Factors influencing overall survival include metastasectomy and ECOG ...

Using AI, we identified publications that likely reported a testing or mutation rate, filtered publications for cancer type, and identified sentences that likely reported rates. Rates and covariates ...

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved Opdivo in combination with Yervoy for the treatment of patients with BRAF V600 wild-type and BRAF ...

Phase III trial results supported recent FDA approval for patients with BRAF V600E mutations Data from this multi-institutional collaboration across 28 countries supported the accelerated approval of ...